Identification

Name
Mephentermine
Accession Number
DB01365
Type
Small Molecule
Groups
Approved
Description

A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)

Structure
Thumb
Synonyms
  • Mephentermine
Product Ingredients
IngredientUNIICASInChI Key
Mephentermine sulfate580655Z8RR 1212-72-2DNKCFBJMFIUNRS-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Wyamine Sulfate Injection Liq 30mg/mlLiquid30 mgIntramuscular; IntravenousWyeth Ayerst Canada Inc.1994-12-311998-12-15Canada
International/Other Brands
Wyamine / Wyfentermina
Categories
UNII
TEZ91L71V4
CAS number
100-92-5
Weight
Average: 163.2594
Monoisotopic: 163.136099549
Chemical Formula
C11H17N
InChI Key
RXQCGGRTAILOIN-UHFFFAOYSA-N
InChI
InChI=1S/C11H17N/c1-11(2,12-3)9-10-7-5-4-6-8-10/h4-8,12H,9H2,1-3H3
IUPAC Name
methyl(2-methyl-1-phenylpropan-2-yl)amine
SMILES
CNC(C)(C)CC1=CC=CC=C1

Pharmacology

Indication

Used to maintain blood pressure in hypotensive states.

Structured Indications
Not Available
Pharmacodynamics

Mephentermine is a sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)

Mechanism of action

Mephentermine is an alpha adrenergic receptor agonist, but also acts indirectly by releasing endogenous norepinephrine. Cardiac output and systolic and diastolic pressures are usually increased. A change in heart rate is variable, depending on the degree of vagal tone. Sometimes the net vascular effect may be vasodilation. Large doses may depress the myocardium or produce central nervous system (CNS) effects.

TargetActionsOrganism
AAlpha adrenergic receptor
agonist
Human
UBeta adrenergic receptor
agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic, by N-demethylation and then p-hydroxylation.

Route of elimination
Not Available
Half life

17 to 18 hours.

Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypertensive activities of Mephentermine.Experimental
AcebutololThe risk or severity of adverse effects can be increased when Acebutolol is combined with Mephentermine.Approved
AcepromazineAcepromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
AceprometazineAceprometazine may decrease the stimulatory activities of Mephentermine.Approved
AcetazolamideAcetazolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved, Vet Approved
AcetophenazineAcetophenazine may decrease the stimulatory activities of Mephentermine.Approved
AcrivastineMephentermine may decrease the sedative activities of Acrivastine.Approved
AlcaftadineMephentermine may decrease the sedative activities of Alcaftadine.Approved
AlfentanilMephentermine may increase the analgesic activities of Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Mephentermine.Approved, Investigational
AlgeldrateAlgeldrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
AlimemazineMephentermine may decrease the sedative activities of Alimemazine.Approved, Vet Approved
AlmagateAlmagate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
AlmasilateAlmasilate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
AloglutamolAloglutamol may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
AlphacetylmethadolMephentermine may increase the analgesic activities of Alphacetylmethadol.Experimental, Illicit
AlphaprodineMephentermine may increase the analgesic activities of Alphaprodine.Illicit
AluminiumAluminium may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Aluminium acetoacetateAluminium acetoacetate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
Aluminium glycinateAluminium glycinate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
Aluminum hydroxideAluminum hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
AmineptineAmineptine may increase the vasopressor activities of Mephentermine.Illicit, Withdrawn
AmisulprideAmisulpride may decrease the stimulatory activities of Mephentermine.Approved, Investigational
AmitriptylineAmitriptyline may increase the vasopressor activities of Mephentermine.Approved
Ammonium chlorideThe serum concentration of Mephentermine can be decreased when it is combined with Ammonium chloride.Approved, Vet Approved
AmperozideAmperozide may decrease the stimulatory activities of Mephentermine.Experimental
AmphetamineThe risk or severity of adverse effects can be increased when Amphetamine is combined with Mephentermine.Approved, Illicit
AntazolineMephentermine may decrease the sedative activities of Antazoline.Approved
AripiprazoleAripiprazole may decrease the stimulatory activities of Mephentermine.Approved, Investigational
AsenapineAsenapine may decrease the stimulatory activities of Mephentermine.Approved
AstemizoleMephentermine may decrease the sedative activities of Astemizole.Approved, Withdrawn
AtomoxetineAtomoxetine may increase the hypertensive activities of Mephentermine.Approved
AzaperoneAzaperone may decrease the stimulatory activities of Mephentermine.Vet Approved
AzatadineMephentermine may decrease the sedative activities of Azatadine.Approved
AzelastineMephentermine may decrease the sedative activities of Azelastine.Approved
BamipineMephentermine may decrease the sedative activities of Bamipine.Experimental
BenmoxinBenmoxin may increase the hypertensive activities of Mephentermine.Withdrawn
BenperidolBenperidol may decrease the stimulatory activities of Mephentermine.Investigational
BenzphetamineThe risk or severity of adverse effects can be increased when Benzphetamine is combined with Mephentermine.Approved, Illicit
Benzylpenicilloyl PolylysineMephentermine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BezitramideMephentermine may increase the analgesic activities of Bezitramide.Experimental, Illicit, Withdrawn
BifeprunoxBifeprunox may decrease the stimulatory activities of Mephentermine.Investigational
Bismuth SubcitrateBismuth Subcitrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Bismuth subnitrateBismuth subnitrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
BrexpiprazoleBrexpiprazole may decrease the stimulatory activities of Mephentermine.Approved
BrofaromineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Brofaromine.Experimental
BromocriptineBromocriptine may increase the hypertensive activities of Mephentermine.Approved, Investigational
BromperidolBromperidol may decrease the stimulatory activities of Mephentermine.Investigational
BrompheniramineMephentermine may decrease the sedative activities of Brompheniramine.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Mephentermine.Investigational
BuclizineMephentermine may decrease the sedative activities of Buclizine.Approved
BunazosinBunazosin may decrease the vasoconstricting activities of Mephentermine.Investigational
BuprenorphineMephentermine may increase the analgesic activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
ButaperazineButaperazine may decrease the stimulatory activities of Mephentermine.Experimental
ButorphanolMephentermine may increase the analgesic activities of Butorphanol.Approved, Illicit, Vet Approved
Butyric AcidMephentermine may decrease the sedative activities of Butyric Acid.Experimental
CabergolineCabergoline may increase the hypertensive activities of Mephentermine.Approved
Calcium CarbonateCalcium Carbonate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Calcium silicateCalcium silicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
CarbinoxamineMephentermine may decrease the sedative activities of Carbinoxamine.Approved
CarfentanilMephentermine may increase the analgesic activities of Carfentanil.Illicit, Vet Approved
CariprazineCariprazine may decrease the stimulatory activities of Mephentermine.Approved
CaroxazoneCaroxazone may increase the hypertensive activities of Mephentermine.Withdrawn
CarvedilolCarvedilol may decrease the vasoconstricting activities of Mephentermine.Approved, Investigational
CeliprololThe risk or severity of adverse effects can be increased when Mephentermine is combined with Celiprolol.Approved, Investigational
CetirizineMephentermine may decrease the sedative activities of Cetirizine.Approved
ChloropyramineMephentermine may decrease the sedative activities of Chloropyramine.Approved
ChlorphenamineMephentermine may decrease the sedative activities of Chlorphenamine.Approved
ChlorphenoxamineMephentermine may decrease the sedative activities of Chlorphenoxamine.Withdrawn
ChlorphentermineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineChlorproethazine may decrease the stimulatory activities of Mephentermine.Experimental
ChlorpromazineChlorpromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
ChlorprothixeneChlorprothixene may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
CimetidineMephentermine may decrease the sedative activities of Cimetidine.Approved
CinnarizineMephentermine may decrease the sedative activities of Cinnarizine.Approved
ClemastineMephentermine may decrease the sedative activities of Clemastine.Approved
ClenbuterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Clenbuterol.Approved, Vet Approved
ClomipramineClomipramine may increase the vasopressor activities of Mephentermine.Approved, Vet Approved
ClopenthixolClopenthixol may decrease the stimulatory activities of Mephentermine.Experimental
ClothiapineClothiapine may decrease the stimulatory activities of Mephentermine.Experimental
ClozapineClozapine may decrease the stimulatory activities of Mephentermine.Approved
CodeineMephentermine may increase the analgesic activities of Codeine.Approved, Illicit
CyamemazineCyamemazine may decrease the stimulatory activities of Mephentermine.Approved
CyclizineMephentermine may decrease the sedative activities of Cyclizine.Approved
CyclobenzaprineCyclobenzaprine may increase the vasopressor activities of Mephentermine.Approved
CyproheptadineMephentermine may decrease the sedative activities of Cyproheptadine.Approved
DapiprazoleDapiprazole may decrease the stimulatory activities of Mephentermine.Approved
DesipramineDesipramine may increase the vasopressor activities of Mephentermine.Approved
DesloratadineMephentermine may decrease the sedative activities of Desloratadine.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Mephentermine.Approved
DexbrompheniramineMephentermine may decrease the sedative activities of Dexbrompheniramine.Approved
DexchlorpheniramineMephentermine may decrease the sedative activities of Dexchlorpheniramine.Experimental
Dexchlorpheniramine maleateMephentermine may decrease the sedative activities of Dexchlorpheniramine maleate.Approved
DextromoramideMephentermine may increase the analgesic activities of Dextromoramide.Experimental, Illicit
DextropropoxypheneMephentermine may increase the analgesic activities of Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineMephentermine may increase the analgesic activities of Dezocine.Approved
DibenzepinDibenzepin may increase the vasopressor activities of Mephentermine.Experimental
DiclofenamideDiclofenamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
DihydrocodeineMephentermine may increase the analgesic activities of Dihydrocodeine.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Mephentermine.Approved
DihydroetorphineMephentermine may increase the analgesic activities of Dihydroetorphine.Experimental, Illicit
DihydromorphineMephentermine may increase the analgesic activities of Dihydromorphine.Experimental, Illicit
DimenhydrinateMephentermine may decrease the sedative activities of Dimenhydrinate.Approved
DimetindeneMephentermine may decrease the sedative activities of Dimetindene.Approved
DimetotiazineMephentermine may decrease the sedative activities of Dimetotiazine.Approved
DiphenhydramineMephentermine may decrease the sedative activities of Diphenhydramine.Approved
DiphenoxylateMephentermine may increase the analgesic activities of Diphenoxylate.Approved, Illicit
DixyrazineDixyrazine may decrease the stimulatory activities of Mephentermine.Experimental
DobutamineThe risk or severity of adverse effects can be increased when Dobutamine is combined with Mephentermine.Approved
DopamineThe risk or severity of adverse effects can be increased when Dopamine is combined with Mephentermine.Approved
DosulepinDosulepin may increase the vasopressor activities of Mephentermine.Approved
DoxazosinDoxazosin may decrease the vasoconstricting activities of Mephentermine.Approved
DoxepinDoxepin may increase the vasopressor activities of Mephentermine.Approved
DoxofyllineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Doxofylline.Approved
DoxylamineMephentermine may decrease the sedative activities of Doxylamine.Approved, Vet Approved
DPDPEMephentermine may increase the analgesic activities of DPDPE.Investigational
DronabinolDronabinol may increase the tachycardic activities of Mephentermine.Approved, Illicit
DroperidolDroperidol may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Mephentermine.Approved
EbastineMephentermine may decrease the sedative activities of Ebastine.Investigational
EcopipamEcopipam may decrease the stimulatory activities of Mephentermine.Investigational
EmedastineMephentermine may decrease the sedative activities of Emedastine.Approved
EpanololThe risk or severity of adverse effects can be increased when Mephentermine is combined with Epanolol.Experimental
EphedrineThe risk or severity of adverse effects can be increased when Ephedrine is combined with Mephentermine.Approved
EpinastineMephentermine may decrease the sedative activities of Epinastine.Approved, Investigational
EpinephrineThe risk or severity of adverse effects can be increased when Epinephrine is combined with Mephentermine.Approved, Vet Approved
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Mephentermine.Approved
ErgonovineErgonovine may increase the hypertensive activities of Mephentermine.Approved
ErgotamineErgotamine may increase the hypertensive activities of Mephentermine.Approved
EsmirtazapineEsmirtazapine may increase the vasopressor activities of Mephentermine.Investigational
EthopropazineMephentermine may decrease the sedative activities of Ethopropazine.Approved
EthosuximideThe therapeutic efficacy of Ethosuximide can be decreased when used in combination with Mephentermine.Approved
EthoxzolamideEthoxzolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Withdrawn
EthylmorphineMephentermine may increase the analgesic activities of Ethylmorphine.Approved, Illicit
EtilefrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Etilefrine.Withdrawn
EtorphineMephentermine may increase the analgesic activities of Etorphine.Illicit, Vet Approved
FamotidineMephentermine may decrease the sedative activities of Famotidine.Approved
FencamfamineFencamfamine may decrease the stimulatory activities of Mephentermine.Approved, Illicit, Withdrawn
FenoterolThe risk or severity of adverse effects can be increased when Fenoterol is combined with Mephentermine.Approved
FenozoloneThe risk or severity of adverse effects can be increased when Mephentermine is combined with Fenozolone.Experimental
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Mephentermine.Approved, Illicit, Investigational, Vet Approved
FexofenadineMephentermine may decrease the sedative activities of Fexofenadine.Approved
FluanisoneFluanisone may decrease the stimulatory activities of Mephentermine.Experimental
FlunarizineMephentermine may decrease the sedative activities of Flunarizine.Approved
FlupentixolFlupentixol may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
FluphenazineFluphenazine may decrease the stimulatory activities of Mephentermine.Approved
FluspirileneFluspirilene may decrease the stimulatory activities of Mephentermine.Approved
FurazolidoneFurazolidone may increase the hypertensive activities of Mephentermine.Approved, Vet Approved
Glutamic AcidThe serum concentration of Mephentermine can be decreased when it is combined with Glutamic Acid.Approved, Nutraceutical
GuanethidineThe serum concentration of Mephentermine can be decreased when it is combined with Guanethidine.Approved
HaloperidolHaloperidol may decrease the stimulatory activities of Mephentermine.Approved
HarmalineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Harmaline.Experimental
HeroinMephentermine may increase the analgesic activities of Heroin.Approved, Illicit
HyaluronidaseHyaluronidase may increase the vasoconstricting activities of Mephentermine.Approved, Investigational
HydracarbazineHydracarbazine may increase the hypertensive activities of Mephentermine.Experimental
HydrocodoneMephentermine may increase the analgesic activities of Hydrocodone.Approved, Illicit
HydromorphoneMephentermine may increase the analgesic activities of Hydromorphone.Approved, Illicit
HydrotalciteHydrotalcite may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
HydroxyamphetamineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Hydroxyamphetamine.Approved
HydroxyzineMephentermine may decrease the sedative activities of Hydroxyzine.Approved
IloperidoneIloperidone may decrease the stimulatory activities of Mephentermine.Approved
ImipramineImipramine may increase the vasopressor activities of Mephentermine.Approved
IndoraminIndoramin may decrease the vasoconstricting activities of Mephentermine.Withdrawn
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Mephentermine.Approved
Ioflupane I-123Mephentermine may decrease effectiveness of Ioflupane I-123 as a diagnostic agent.Approved
IprindoleIprindole may increase the vasopressor activities of Mephentermine.Experimental
IproclozideIproclozide may increase the hypertensive activities of Mephentermine.Withdrawn
IproniazidIproniazid may increase the hypertensive activities of Mephentermine.Withdrawn
IsocarboxazidIsocarboxazid may increase the hypertensive activities of Mephentermine.Approved
IsoprenalineThe risk or severity of adverse effects can be increased when Isoprenaline is combined with Mephentermine.Approved
IsothipendylMephentermine may decrease the sedative activities of Isothipendyl.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Isoxsuprine.Approved, Withdrawn
KetobemidoneMephentermine may increase the analgesic activities of Ketobemidone.Approved
KetotifenMephentermine may decrease the sedative activities of Ketotifen.Approved
LabetalolLabetalol may decrease the vasoconstricting activities of Mephentermine.Approved
LafutidineMephentermine may decrease the sedative activities of Lafutidine.Investigational
LavoltidineMephentermine may decrease the sedative activities of Lavoltidine.Investigational
LevocabastineMephentermine may decrease the sedative activities of Levocabastine.Approved
LevocetirizineMephentermine may decrease the sedative activities of Levocetirizine.Approved
Levomethadyl AcetateMephentermine may increase the analgesic activities of Levomethadyl Acetate.Approved
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Mephentermine.Approved
LevorphanolMephentermine may increase the analgesic activities of Levorphanol.Approved
LinezolidLinezolid may increase the hypertensive activities of Mephentermine.Approved, Investigational
LithiumLithium may decrease the stimulatory activities of Mephentermine.Approved
LodoxamideMephentermine may decrease the sedative activities of Lodoxamide.Approved
LofentanilMephentermine may increase the analgesic activities of Lofentanil.Illicit
LofepramineLofepramine may increase the vasopressor activities of Mephentermine.Experimental
LoratadineMephentermine may decrease the sedative activities of Loratadine.Approved
LoxapineLoxapine may decrease the stimulatory activities of Mephentermine.Approved
LurasidoneLurasidone may decrease the stimulatory activities of Mephentermine.Approved
MagaldrateMagaldrate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Withdrawn
Magnesium HydroxideMagnesium Hydroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Magnesium oxideMagnesium oxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
Magnesium peroxideMagnesium peroxide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
Magnesium silicateMagnesium silicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Experimental
Magnesium TrisilicateMagnesium Trisilicate may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MebanazineMebanazine may increase the hypertensive activities of Mephentermine.Withdrawn
MeclizineMephentermine may decrease the sedative activities of Meclizine.Approved
MefenorexThe risk or severity of adverse effects can be increased when Mephentermine is combined with Mefenorex.Experimental
MelperoneMelperone may decrease the stimulatory activities of Mephentermine.Approved
MeptazinolMephentermine may increase the analgesic activities of Meptazinol.Experimental
MepyramineMephentermine may decrease the sedative activities of Mepyramine.Approved, Vet Approved
MequitazineMephentermine may decrease the sedative activities of Mequitazine.Approved
MesoridazineMesoridazine may decrease the stimulatory activities of Mephentermine.Approved
MetaraminolThe risk or severity of adverse effects can be increased when Metaraminol is combined with Mephentermine.Approved, Investigational
MethadoneMephentermine may increase the analgesic activities of Methadone.Approved
Methadyl AcetateMephentermine may increase the analgesic activities of Methadyl Acetate.Approved, Illicit
MethamphetamineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Methamphetamine.Approved, Illicit
MethapyrileneMephentermine may decrease the sedative activities of Methapyrilene.Withdrawn
MethazolamideMethazolamide may decrease the excretion rate of Mephentermine which could result in a higher serum level.Approved
MethenamineThe serum concentration of Mephentermine can be decreased when it is combined with Methenamine.Approved, Vet Approved
MethotrimeprazineMethotrimeprazine may decrease the stimulatory activities of Mephentermine.Approved
MethoxamineThe risk or severity of adverse effects can be increased when Methoxamine is combined with Mephentermine.Approved
Methylene blueMethylene blue may increase the hypertensive activities of Mephentermine.Investigational
MethylergometrineMethylergometrine may increase the hypertensive activities of Mephentermine.Approved
MetiamideMephentermine may decrease the sedative activities of Metiamide.Experimental
MianserinMephentermine may decrease the sedative activities of Mianserin.Approved
MidodrineThe risk or severity of adverse effects can be increased when Midodrine is combined with Mephentermine.Approved
MilnacipranMilnacipran may increase the tachycardic activities of Mephentermine.Approved
MinaprineMinaprine may increase the hypertensive activities of Mephentermine.Approved
MirtazapineMirtazapine may increase the vasopressor activities of Mephentermine.Approved
MizolastineMephentermine may decrease the sedative activities of Mizolastine.Investigational
MoclobemideMoclobemide may increase the hypertensive activities of Mephentermine.Approved
MolindoneMolindone may decrease the stimulatory activities of Mephentermine.Approved
MoperoneMoperone may decrease the stimulatory activities of Mephentermine.Experimental
MorphineMephentermine may increase the analgesic activities of Morphine.Approved, Investigational
MosapramineMosapramine may decrease the stimulatory activities of Mephentermine.Experimental
NabiloneNabilone may increase the tachycardic activities of Mephentermine.Approved, Investigational
NalbuphineMephentermine may increase the analgesic activities of Nalbuphine.Approved
NialamideNialamide may increase the hypertensive activities of Mephentermine.Withdrawn
NicomorphineMephentermine may increase the analgesic activities of Nicomorphine.Experimental
NizatidineMephentermine may decrease the sedative activities of Nizatidine.Approved
NorepinephrineThe risk or severity of adverse effects can be increased when Norepinephrine is combined with Mephentermine.Approved
NormethadoneMephentermine may increase the analgesic activities of Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the vasopressor activities of Mephentermine.Approved
NylidrinThe risk or severity of adverse effects can be increased when Mephentermine is combined with Nylidrin.Approved
OctamoxinOctamoxin may increase the hypertensive activities of Mephentermine.Withdrawn
OlanzapineOlanzapine may decrease the stimulatory activities of Mephentermine.Approved, Investigational
OlopatadineMephentermine may decrease the sedative activities of Olopatadine.Approved
OndansetronOndansetron may decrease the stimulatory activities of Mephentermine.Approved
OpipramolOpipramol may increase the vasopressor activities of Mephentermine.Investigational
OpiumMephentermine may increase the analgesic activities of Opium.Approved, Illicit
OrciprenalineThe risk or severity of adverse effects can be increased when Orciprenaline is combined with Mephentermine.Approved
OsanetantOsanetant may decrease the stimulatory activities of Mephentermine.Investigational
OxatomideMephentermine may decrease the sedative activities of Oxatomide.Investigational
OxycodoneMephentermine may increase the analgesic activities of Oxycodone.Approved, Illicit, Investigational
OxymetazolineThe risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephentermine.Approved
OxymorphoneMephentermine may increase the analgesic activities of Oxymorphone.Approved, Investigational, Vet Approved
OxypertineOxypertine may decrease the stimulatory activities of Mephentermine.Experimental
OzagrelMephentermine may decrease the sedative activities of Ozagrel.Investigational
PaliperidonePaliperidone may decrease the stimulatory activities of Mephentermine.Approved
PargylinePargyline may increase the hypertensive activities of Mephentermine.Approved
PemirolastMephentermine may decrease the sedative activities of Pemirolast.Approved
PenfluridolPenfluridol may decrease the stimulatory activities of Mephentermine.Experimental
PentazocineMephentermine may increase the analgesic activities of Pentazocine.Approved, Vet Approved
PerazinePerazine may decrease the stimulatory activities of Mephentermine.Investigational
PerospironePerospirone may decrease the stimulatory activities of Mephentermine.Approved
PerphenazinePerphenazine may decrease the stimulatory activities of Mephentermine.Approved
PethidineMephentermine may increase the analgesic activities of Pethidine.Approved
PhenazocineMephentermine may increase the analgesic activities of Phenazocine.Experimental
PhenelzinePhenelzine may increase the hypertensive activities of Mephentermine.Approved
PhenindamineMephentermine may decrease the sedative activities of Phenindamine.Approved
PheniprazinePheniprazine may increase the hypertensive activities of Mephentermine.Withdrawn
PheniramineMephentermine may decrease the sedative activities of Pheniramine.Approved
PhenmetrazineThe risk or severity of adverse effects can be increased when Phenmetrazine is combined with Mephentermine.Approved, Illicit
PhenobarbitalThe serum concentration of Phenobarbital can be decreased when it is combined with Mephentermine.Approved
PhenoperidineMephentermine may increase the analgesic activities of Phenoperidine.Experimental
PhenoxypropazinePhenoxypropazine may increase the hypertensive activities of Mephentermine.Withdrawn
PhentermineThe risk or severity of adverse effects can be increased when Phentermine is combined with Mephentermine.Approved, Illicit
PhenylephrineThe risk or severity of adverse effects can be increased when Phenylephrine is combined with Mephentermine.Approved
PhenylpropanolamineThe risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Mephentermine.Approved, Vet Approved, Withdrawn
PhenytoinThe serum concentration of Phenytoin can be decreased when it is combined with Mephentermine.Approved, Vet Approved
PimozidePimozide may decrease the stimulatory activities of Mephentermine.Approved
PipamperonePipamperone may decrease the stimulatory activities of Mephentermine.Approved
PipotiazinePipotiazine may decrease the stimulatory activities of Mephentermine.Approved
PiritramideMephentermine may increase the analgesic activities of Piritramide.Investigational
PirlindolePirlindole may increase the hypertensive activities of Mephentermine.Approved
PivhydrazinePivhydrazine may increase the hypertensive activities of Mephentermine.Withdrawn
PrazosinPrazosin may decrease the vasoconstricting activities of Mephentermine.Approved
PrenalterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Prenalterol.Experimental
ProcaterolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Procaterol.Approved
ProchlorperazineProchlorperazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
PromazinePromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
PromethazineMephentermine may decrease the sedative activities of Promethazine.Approved
PropericiazinePropericiazine may decrease the stimulatory activities of Mephentermine.Approved
ProthipendylProthipendyl may decrease the stimulatory activities of Mephentermine.Investigational
ProtriptylineProtriptyline may increase the vasopressor activities of Mephentermine.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Pseudoephedrine.Approved
QuetiapineQuetiapine may decrease the stimulatory activities of Mephentermine.Approved
QuifenadineMephentermine may decrease the sedative activities of Quifenadine.Experimental
RacepinephrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Racepinephrine.Approved
RacloprideRaclopride may decrease the stimulatory activities of Mephentermine.Investigational
RanitidineMephentermine may decrease the sedative activities of Ranitidine.Approved
RasagilineRasagiline may increase the hypertensive activities of Mephentermine.Approved
RemifentanilMephentermine may increase the analgesic activities of Remifentanil.Approved
RemoxiprideRemoxipride may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
ReserpineReserpine may decrease the stimulatory activities of Mephentermine.Approved
RisperidoneRisperidone may decrease the stimulatory activities of Mephentermine.Approved, Investigational
RitanserinRitanserin may decrease the stimulatory activities of Mephentermine.Investigational
RitodrineThe risk or severity of adverse effects can be increased when Ritodrine is combined with Mephentermine.Approved
Roxatidine acetateMephentermine may decrease the sedative activities of Roxatidine acetate.Approved
SafrazineSafrazine may increase the hypertensive activities of Mephentermine.Withdrawn
SelegilineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleSertindole may decrease the stimulatory activities of Mephentermine.Approved, Withdrawn
SilodosinSilodosin may decrease the vasoconstricting activities of Mephentermine.Approved
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Mephentermine.Approved
SufentanilMephentermine may increase the analgesic activities of Sufentanil.Approved, Investigational
SulpirideSulpiride may decrease the stimulatory activities of Mephentermine.Approved
SultoprideSultopride may decrease the stimulatory activities of Mephentermine.Experimental
SynephrineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Synephrine.Experimental
TamsulosinTamsulosin may decrease the vasoconstricting activities of Mephentermine.Approved, Investigational
TapentadolMephentermine may increase the analgesic activities of Tapentadol.Approved
Tedizolid PhosphateTedizolid Phosphate may increase the hypertensive activities of Mephentermine.Approved
TerazosinTerazosin may decrease the vasoconstricting activities of Mephentermine.Approved
TerbutalineThe risk or severity of adverse effects can be increased when Terbutaline is combined with Mephentermine.Approved
TerfenadineMephentermine may decrease the sedative activities of Terfenadine.Withdrawn
TesmilifeneMephentermine may decrease the sedative activities of Tesmilifene.Investigational
TetrahydropalmatineTetrahydropalmatine may decrease the stimulatory activities of Mephentermine.Investigational
TetryzolineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tetryzoline.Approved
ThiopropazateThiopropazate may decrease the stimulatory activities of Mephentermine.Experimental
ThioproperazineThioproperazine may decrease the stimulatory activities of Mephentermine.Approved
ThioridazineThioridazine may decrease the stimulatory activities of Mephentermine.Withdrawn
ThiothixeneThiothixene may decrease the stimulatory activities of Mephentermine.Approved
ThonzylamineMephentermine may decrease the sedative activities of Thonzylamine.Approved
TianeptineTianeptine may increase the vasopressor activities of Mephentermine.Approved
TiaprideTiapride may decrease the stimulatory activities of Mephentermine.Approved, Investigational
TilidineMephentermine may increase the analgesic activities of Tilidine.Experimental
ToloxatoneToloxatone may increase the hypertensive activities of Mephentermine.Approved
TramadolMephentermine may increase the analgesic activities of Tramadol.Approved, Investigational
TramazolineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tramazoline.Investigational
TranilastMephentermine may decrease the sedative activities of Tranilast.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypertensive activities of Mephentermine.Experimental
TranylcypromineTranylcypromine may increase the hypertensive activities of Mephentermine.Approved
TretoquinolThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tretoquinol.Experimental
TrifluoperazineTrifluoperazine may decrease the stimulatory activities of Mephentermine.Approved
TrifluperidolTrifluperidol may decrease the stimulatory activities of Mephentermine.Experimental
TriflupromazineTriflupromazine may decrease the stimulatory activities of Mephentermine.Approved, Vet Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Mephentermine.Experimental
TrimipramineTrimipramine may increase the vasopressor activities of Mephentermine.Approved
TripelennamineMephentermine may decrease the sedative activities of Tripelennamine.Approved, Vet Approved
TriprolidineMephentermine may decrease the sedative activities of Triprolidine.Approved
TritoqualineMephentermine may decrease the sedative activities of Tritoqualine.Experimental
TyramineThe risk or severity of adverse effects can be increased when Mephentermine is combined with Tyramine.Investigational, Nutraceutical
UrapidilUrapidil may decrease the vasoconstricting activities of Mephentermine.Investigational
VenlafaxineVenlafaxine may increase the tachycardic activities of Mephentermine.Approved
VeraliprideVeralipride may decrease the stimulatory activities of Mephentermine.Experimental
Vitamin CThe serum concentration of Mephentermine can be decreased when it is combined with Vitamin C.Approved, Nutraceutical
ZiprasidoneZiprasidone may decrease the stimulatory activities of Mephentermine.Approved
ZotepineZotepine may decrease the stimulatory activities of Mephentermine.Approved
ZuclopenthixolZuclopenthixol may decrease the stimulatory activities of Mephentermine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference
Not Available
General References
Not Available
External Links
Human Metabolome Database
HMDB15452
KEGG Compound
C07889
PubChem Compound
3677
PubChem Substance
46505918
ChemSpider
3549
BindingDB
81455
ChEBI
6755
ChEMBL
CHEMBL1201234
Therapeutic Targets Database
DAP000898
PharmGKB
PA164745533
ATC Codes
C01CA11 — Mephentermine
AHFS Codes
Not Available
PDB Entries
Not Available
FDA label
Not Available
MSDS
Not Available

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous30 mg
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
PropertyValueSource
melting point (°C)< 25 °CPhysProp
Predicted Properties
PropertyValueSource
Water Solubility0.457 mg/mLALOGPS
logP2.54ALOGPS
logP2.52ChemAxon
logS-2.6ALOGPS
pKa (Strongest Basic)10.3ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area12.03 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity53.12 m3·mol-1ChemAxon
Polarizability19.79 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9925
Blood Brain Barrier+0.9664
Caco-2 permeable+0.7962
P-glycoprotein substrateNon-substrate0.5711
P-glycoprotein inhibitor INon-inhibitor0.8782
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.775
CYP450 2C9 substrateNon-substrate0.7797
CYP450 2D6 substrateSubstrate0.7109
CYP450 3A4 substrateNon-substrate0.5507
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.923
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8388
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8682
Ames testNon AMES toxic0.979
CarcinogenicityNon-carcinogens0.8079
BiodegradationNot ready biodegradable0.9633
Rat acute toxicity2.8952 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9804
hERG inhibition (predictor II)Non-inhibitor0.872
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)
Download (7.87 KB)
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of chemical entities known as amphetamines and derivatives. These are organic compounds containing or derived from 1-phenylpropan-2-amine.
Kingdom
Chemical entities
Super Class
Organic compounds
Class
Benzenoids
Sub Class
Benzene and substituted derivatives
Direct Parent
Amphetamines and derivatives
Alternative Parents
Phenylpropanes / Aralkylamines / Dialkylamines / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Amphetamine or derivatives / Phenylpropane / Aralkylamine / Secondary amine / Secondary aliphatic amine / Organic nitrogen compound / Organopnictogen compound / Hydrocarbon derivative / Organonitrogen compound / Amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
amphetamines (CHEBI:6755 )

Targets

Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Agonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Ahlquist RP: Present state of alpha- and beta-adrenergic drugs I. The adrenergic receptor. Am Heart J. 1976 Nov;92(5):661-4. [PubMed:10722 ]
  2. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A: Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. 2010 Dec;65(12):1200-5. doi: 10.1111/j.1365-2044.2010.06559.x. [PubMed:21182601 ]
Kind
Protein group
Organism
Human
Pharmacological action
Unknown
Actions
Agonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...

Components:
References
  1. Mohta M, Janani SS, Sethi AK, Agarwal D, Tyagi A: Comparison of phenylephrine hydrochloride and mephentermine sulphate for prevention of post spinal hypotension. Anaesthesia. 2010 Dec;65(12):1200-5. doi: 10.1111/j.1365-2044.2010.06559.x. [PubMed:21182601 ]

Drug created on July 06, 2007 13:56 / Updated on October 02, 2017 04:57